Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients
Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by 4.1 vs. 1 for placebo (p<0.0001), to

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers